Article Abstract

Changes of tryptase in patients with hepatocellular carcinoma after transarterial chemoembolization

Authors: Xu-Li Min, Lin Yang, Xiao-Ming Zhang, Yi Zhou, Nan-Dong Miao, Yong-Jun Ren, Hao Xu, Kang Liu, Juan Peng, Ke Yang

Abstract

Background: To explore the dynamic changes of tryptase in hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) treatment and to determine whether the tryptase level changes in response to TACE.
Methods: The serum levels of tryptase were detected in 40 patients with HCC 1 day prior to TACE procedure, as well as 1, 7, and 28 days after TACE treatment by using enzyme-linked immune-sorbent assays (ELISAs). The difference in serum tryptase levels before and after chemoembolization therapy was examined using analysis of variance. A t-test was performed for comparisons between two response groups.
Results: The levels of tryptase in this group 1 day before TACE, and 1, 7 and 28 days after TACE were 4.85±2.46, 3.32±1.76, 3.15±1.67 and 4.85±2.50 ng/mL, respectively. The tryptase levels before and after TACE treatment were significantly different (F=48.461, P=0.000). The levels of tryptase decreased markedly on day 1 and 7 after TACE and were recovered to the pre-TACE level on day 28 after TACE. Partial response (PR), stable disease (SD) and progressive disease (PD) were observed in 13 (32.5%), 12 (30.0%) and 15 (37.5%) patients, respectively; none of the patients achieved a complete response (CR). The serum levels of tryptase in responsive group (CR + PR) were significantly lower than those in non-responsive group (SD + PD) 28 days after TACE (3.54±1.16 vs. 5.48±2.74 ng/mL, respectively; t=2.426, P=0.020).
Conclusions: The level of serum tryptase in patients with HCC after TACE shows a dynamic change that may be used to evaluate the response to TACE.

Refbacks

  • There are currently no refbacks.